Sign in
Not yet recruitingPhase 4

A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normai FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative

Key facts

Who runs it
Martin-Luther-Universitaet Halle-Wittenberg
Where
Germany, Italy, and Spain7 sites in 3 countriesChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
138 people, planned
Started
28 Feb 2026
Expected to end
30 Jun 2028
Type of study
Interventional
Record updated
25 May 2026

Who can take part

Age
18 years to 64 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male with an age ≥ 18 years old ≤ 55 years old
  • BMI < 35 kg/m2
  • Male infertility of at least 12 months (ICMART definition)
  • Sperm concentration ≥ 1 million/ml and ≤ 16 million/ml at screening
  • Normal FSH serum levels (1.5-8 IU/mL) at screening
  • Normal LH serum levels (at least 1.5 IU/ml) at screening
  • Low testosterone serum levels (between 210 and 350 ng/dL, corresponding to 7.3-12.1nmol/L) at screening
  • Normal serum prolactin and thyroid-stimulating hormone (TSH) values as measured in a local lab
  • Have not received gonadotropin, aromatase inhibitors and SERMs at least 3 months before the start of screening
  • No clinically significant abnormal findings in the screening haematology, biochemistry, and urinalysis parameters

Who cannot take part

  • Patients that received testosterone therapy at any time during the previous 12 months of the study screening
  • Signs of testicular inflammation and or infection, as well as signs of obstruction (including testicular volume higher than 25 mL at ultrasound examination)
  • At Screening and during the study period the presence of an uncontrolled chronic disease (ongoing acute episodes or inadequate treatments), such as diabetes mellitus, thyroid disorders, autoimmune diseases such as arthritis, vasculitis or inflammatory bowel disease
  • Presence of active malignancies
  • Patients with history of gonadotoxic treatments
  • Patients with a history of anabolic steroid use
  • Diagnosed genetic mutations responsible for abnormal sperm concentration (e.g., YCMD, CFTR gene mutations)
  • Patients with clinical varicocele (any grade)
  • Patients with one testis

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where is this trial?

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the impact of the combined administration of r-hFSH-alfa originator plus hCG compared to no treatment on sperm concentration in men with lowered semen analysis, low testosterone serum levels and normai FSH serum levels.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
Criteria questions
Built from 2025-525005-20-00, who can take part
Record updated
25 May 2026